Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 10:46AM ET
0.0437
Dollar change
-0.0155
Percentage change
-26.18
%
Index- P/E- EPS (ttm)-0.65 Insider Own11.84% Shs Outstand144.44M Perf Week-89.16%
Market Cap5.80M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float116.93M Perf Month-88.05%
Income-63.00M PEG- EPS next Q- Inst Own31.65% Short Float9.38% Perf Quarter-86.42%
Sales1.78M P/S3.26 EPS this Y3.51% Inst Trans27.93% Short Ratio2.16 Perf Half Y-95.30%
Book/sh-0.02 P/B- EPS next Y- ROA-55.51% Short Interest10.96M Perf Year-94.27%
Cash/sh0.37 P/C0.12 EPS next 5Y- ROE-1103.79% 52W Range0.05 - 2.51 Perf YTD-89.41%
Dividend Est.- P/FCF- EPS past 5Y44.15% ROI-87.23% 52W High-98.26% Beta0.95
Dividend TTM- Quick Ratio2.09 Sales past 5Y0.00% Gross Margin-94.96% 52W Low-15.64% ATR (14)0.05
Dividend Ex-Date- Current Ratio2.16 EPS Y/Y TTM49.72% Oper. Margin-3843.16% RSI (14)22.10 Volatility21.13% 11.77%
Employees148 Debt/Eq- Sales Y/Y TTM- Profit Margin-3531.17% Recom1.50 Target Price4.33
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q79.97% Payout- Rel Volume28.20 Prev Close0.06
Sales Surprise-34.19% EPS Surprise113.11% Sales Q/Q- EarningsMar 27 BMO Avg Volume5.08M Price0.04
SMA20-87.14% SMA50-87.62% SMA200-94.66% Trades Volume33,683,749 Change-26.18%
Date Action Analyst Rating Change Price Target Change
Nov-01-21Initiated Alliance Global Partners Buy $11
Jul-01-20Initiated Evercore ISI Outperform
May-26-20Initiated Piper Sandler Overweight $13
Apr-27-20Initiated H.C. Wainwright Buy $15
Nov-26-18Initiated Needham Buy $23
Nov-21-18Initiated Oppenheimer Outperform $15
Nov-20-18Initiated RBC Capital Mkts Outperform $20
Mar-27-24 11:19PM
11:53AM
11:16AM
07:00AM
07:00AM
08:00AM Loading…
Mar-22-24 08:00AM
Feb-23-24 08:00AM
Jan-29-24 06:00AM
Jan-17-24 08:00AM
Dec-20-23 08:05AM
Nov-27-23 08:11PM
Nov-20-23 08:00AM
Nov-15-23 09:15AM
02:45AM
Nov-14-23 07:30AM
07:00AM Loading…
07:00AM
Nov-04-23 08:00AM
Nov-01-23 08:00AM
Oct-16-23 04:39PM
Oct-09-23 02:00PM
Oct-02-23 08:00AM
Sep-28-23 08:00AM
Sep-27-23 04:30PM
Aug-31-23 08:00AM
Aug-15-23 02:30AM
Aug-14-23 07:27AM
07:00AM
Aug-01-23 08:00AM
Jul-11-23 08:00AM
Jul-10-23 02:00PM
09:55AM Loading…
Jun-20-23 09:55AM
Jun-14-23 04:30PM
Jun-09-23 09:55AM
May-31-23 04:30PM
07:00AM
May-22-23 08:00AM
May-17-23 07:27AM
May-15-23 04:18PM
04:05PM
May-11-23 05:20PM
Apr-20-23 07:24AM
Apr-19-23 08:15AM
Apr-18-23 07:16PM
12:35PM
Apr-17-23 04:16PM
Mar-29-23 07:28AM
Mar-28-23 02:12PM
Mar-27-23 07:00AM
Mar-20-23 04:30PM
08:00AM
Mar-12-23 10:10AM
Mar-07-23 08:00AM
Feb-18-23 12:30PM
Jan-16-23 12:00PM
Dec-12-22 07:00AM
Nov-23-22 08:00AM
Nov-21-22 04:52PM
Nov-14-22 07:00AM
Nov-10-22 08:00AM
Nov-07-22 08:00AM
08:00AM
Nov-03-22 09:07AM
Oct-10-22 07:00AM
Sep-29-22 07:00AM
Sep-28-22 12:08AM
12:08AM
Sep-27-22 04:06PM
Sep-22-22 05:27AM
Sep-19-22 07:00AM
Sep-12-22 08:00AM
Aug-15-22 03:00PM
07:00AM
Aug-10-22 07:00AM
Aug-09-22 10:39AM
Aug-08-22 08:00AM
Aug-04-22 07:29AM
Aug-01-22 07:00AM
Jun-13-22 07:00AM
Jun-10-22 07:00AM
Jun-02-22 07:00AM
Jun-01-22 04:30PM
07:00AM
May-17-22 04:30PM
May-10-22 07:00AM
May-05-22 03:36PM
07:00AM
May-03-22 08:00AM
Apr-27-22 12:31PM
07:00AM
Apr-26-22 09:20AM
07:00AM
Apr-25-22 08:00PM
04:05PM
07:00AM
Apr-21-22 08:05AM
Apr-20-22 04:05PM
Apr-07-22 08:00AM
Mar-30-22 07:43AM
Mar-29-22 10:12AM
09:40AM
Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA.